Valuation: Alector, Inc.

Market Cap 27Cr 23Cr 22Cr 20Cr 37Cr 2.59TCr 38Cr 256.44Cr 100.42Cr 1.3TCr 101.88Cr 100Cr 4.3TCr P/E 2026 *
-2.83x
P/E 2027 * -3.49x
Enterprise Value 4.39Cr 3.76Cr 3.51Cr 3.22Cr 6.06Cr 419.2Cr 6.16Cr 41Cr 16Cr 210.24Cr 16Cr 16Cr 695.14Cr EV / Sales 2026 *
4x
EV / Sales 2027 * -0.97x
Free-Float
90.37%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day-0.62%
1 week+13.02%
Current month+60.93%
1 month+62.00%
3 months+15.17%
6 months+20.90%
Current year+55.77%
1 week 1.9
Extreme 1.9
2.52
1 month 1.42
Extreme 1.42
2.52
Current year 1.37
Extreme 1.37
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
8.9
5 years 0.87
Extreme 0.87
29.3
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 01/05/2013
Director of Finance/CFO 52 20/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2017
Director TitleAgeSince
Director/Board Member 71 01/05/2013
Director/Board Member 72 01/10/2018
Chairman 77 13/06/2023
Date Insider Type Main position Quantity % Market Cap.
09/07/26 Free

Controller/Auditor

20,000 0.0180%
26/02/26 Sell

Controller/Auditor

4,079 0.0037%
05/12/25 Sell

Controller/Auditor

4,753 0.0044%
Change 5-day change 1-year change 3-year change Capi.($)
-1.23%+13.02%+12.50%-66.11% 27Cr
-1.90%+3.12%+81.70%+110.88% 7.22TCr
+0.43%+17.07%+56.82%+93.64% 6.4TCr
-1.53%-1.22%+2.71%+501.29% 2.85TCr
+3.63%+8.57%+62.12%+24.72% 2.51TCr
-4.64%+21.98%+1.54%+2.50% 2.84TCr
-0.58%+5.98%+39.03%-13.99% 2TCr
0.00%-2.78%+247.46%+423.83% 1.82TCr
+1.81%+1.43%+23.67%+527.06% 1.6TCr
-0.41%+7.96%+44.96%+157.77% 1.35TCr
Average -0.32%+6.45%+57.25%+176.16% 2.86TCr
Weighted average by Cap. -0.56%+6.70%+61.10%+164.05%

Financials

2026 *2027 *
Net sales 1.1Cr 94.15L 87.92L 80.66L 1.52Cr 104.91Cr 1.54Cr 10Cr 4.06Cr 53Cr 4.12Cr 4.03Cr 173.97Cr 2.62Cr 2.24Cr 2.1Cr 1.92Cr 3.62Cr 250.11Cr 3.68Cr 25Cr 9.68Cr 125.44Cr 9.83Cr 9.61Cr 414.75Cr
Net income -9.69Cr -8.31Cr -7.76Cr -7.12Cr -13Cr -925.77Cr -14Cr -92Cr -36Cr -464.31Cr -36Cr -36Cr -1.54TCr -9.8Cr -8.41Cr -7.85Cr -7.2Cr -14Cr -937.03Cr -14Cr -93Cr -36Cr -469.95Cr -37Cr -36Cr -1.55TCr
Net Debt -23Cr -20Cr -18Cr -17Cr -31Cr -2.17TCr -32Cr -214.99Cr -84Cr -1.09TCr -85Cr -84Cr -3.61TCr -30Cr -25Cr -24Cr -22Cr -41Cr -2.84TCr -42Cr -280.49Cr -109.83Cr -1.42TCr -111.43Cr -109Cr -4.7TCr
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
20/26/20 $2.430 +9.95% 37,55,621
18/26/18 $2.210 +7.80% 47,74,016
17/26/17 $2.050 +4.59% 9,13,807
14/26/14 $1.960 -3.92% 6,49,021
13/26/13 $2.040 -5.12% 12,94,760
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.430USD
Average target price
3.100USD
Spread / Average Target
+27.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock